FLT3 and acute myeloid leukemia: Accordingly, in vitro studies illustrated the response of AML cells with non-ITD JMD mutations to pharmacologic FLT3 inhibition (9, 10, 12, 14–16), which supports the idea to use any of the approved TKIs in patients with this type of mutation (5).